Sumitomo Mitsui Trust Group Inc. Grows Stock Holdings in Humana Inc. (NYSE:HUM)

Sumitomo Mitsui Trust Group Inc. raised its stake in Humana Inc. (NYSE:HUM) by 1.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 330,906 shares of the insurance provider’s stock after buying an additional 5,497 shares during the period. Sumitomo Mitsui Trust Group Inc. owned approximately 0.27% of Humana worth $83,954,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of HUM. Atlas Brown Inc. increased its stake in Humana by 0.6% in the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock valued at $1,611,000 after purchasing an additional 38 shares in the last quarter. Moors & Cabot Inc. grew its holdings in Humana by 2.5% in the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock valued at $519,000 after purchasing an additional 40 shares during the last quarter. Mather Group LLC. increased its position in shares of Humana by 21.0% in the fourth quarter. Mather Group LLC. now owns 236 shares of the insurance provider’s stock valued at $60,000 after buying an additional 41 shares in the last quarter. OLD National Bancorp IN raised its stake in shares of Humana by 1.8% during the 3rd quarter. OLD National Bancorp IN now owns 2,613 shares of the insurance provider’s stock worth $828,000 after buying an additional 45 shares during the last quarter. Finally, Your Advocates Ltd. LLP boosted its position in shares of Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.32% of the stock is owned by insiders.

Humana Stock Down 2.0 %

Shares of HUM opened at $274.06 on Monday. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company’s fifty day moving average is $274.21 and its two-hundred day moving average is $298.14. The firm has a market cap of $33.00 billion, a PE ratio of 24.27, a price-to-earnings-growth ratio of 2.11 and a beta of 0.56. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67.

Wall Street Analyst Weigh In

HUM has been the subject of several recent research reports. Barclays raised their target price on shares of Humana from $253.00 to $255.00 and gave the company an “equal weight” rating in a report on Wednesday, January 22nd. Piper Sandler raised their price objective on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and upped their target price for the company from $247.00 to $308.00 in a research note on Wednesday, November 6th. Morgan Stanley raised their price target on Humana from $288.00 to $301.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 17th. Finally, TD Cowen boosted their price target on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Nineteen equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $297.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.